Remix Therapeutics

Reprogramming RNA to transform patients’ lives.

Learn More

Current Beat

Oct | 31 | 2024
Press Release
Remix Therapeutics™ Announces Publication in Science that Reveals Unprecedented Insights into Spliceosome Regulation and Alternative Splicing
Watertown, Mass. (October 31, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the publication of a collaborative research study with Prof. Juan Valcárcel at the Center for Genomic Regulation in Barcelona, Spain in the prestigious journal Science. The research article, titled […]
Read More
Jul | 10 | 2024
Press Release
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
The collaboration leverages Remix’s REMasterTM platform to discover novel drugs for a diverse range of target classes  Remix is eligible to receive up to $1 billion in milestone payments and royalties Watertown, Mass. (July 10th, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers […]
Read More
Jun | 18 | 2024
Press Release
Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix’s Board of Directors Watertown, Mass. (June 18, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Maria Koehler, M.D., Ph.D., as an […]
Read More
May | 2 | 2024
Press Release
Remix Therapeutics™ Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS)
REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to two clinical studies to evaluate safety and clinical activity in ACC and AML/MDS   Watertown, Mass. (May 2, 2024) – Remix Therapeutics (Remix), a […]
Read More

REMaster™ Drug
Discovery Platform

Our proprietary platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease drivers.
Learn More
Data Science
Identifying druggable high value targets
Biology &
Biomolecular Sciences
Functional target validation and multiplexed HTS assays
Medicinal &
Computational Chemistry
Compound identification and optimization from proprietary library

It's Sound Science

About Us
Remix™ launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
About Us
Join Us

Become a Remixer

Remix™ welcomes new people and perspectives to join us in pushing scientific boundaries to offer new hope to patients.
Join the Team

Contact

General Inquiry